ID23771A - Turunan epotilon - Google Patents

Turunan epotilon

Info

Publication number: ID23771A
Authority: ID; Indonesia
Prior art keywords: alkyl; group; substituted; aryl; cycloalkyl
Prior art date: 1997-07-08

Application number

IDW20000002A

Other languages

English (en)

Indonesian (id)

Inventor

Gregory D Vite

Robertr M Borzilleri

Soong-Hoon Kim

James A Johnson

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-07-08

Filing date

1998-06-16

Publication date

2000-05-11

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26729990&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ID23771(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1998-06-16 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

2000-05-11 Publication of ID23771A publication Critical patent/ID23771A/id

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
- C07D225/02—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom not condensed with other rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Pyrane Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Thiazole And Isothizaole Compounds (AREA)

IDW20000002A 1997-07-08 1998-06-16 Turunan epotilon ID23771A (id)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US5195197P	1997-07-08	1997-07-08
US6752497P	1997-12-04	1997-12-04

Publications (1)

Publication Number	Publication Date
ID23771A true ID23771A (id)	2000-05-11

Family

ID=26729990

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IDW20000002A ID23771A (id)	1997-07-08	1998-06-16	Turunan epotilon

Country Status (32)

Country	Link
US (10)	US6605599B1 (pl)
EP (4)	EP1493738B1 (pl)
JP (2)	JP4090514B2 (pl)
KR (1)	KR100569041B1 (pl)
CN (1)	CN100384834C (pl)
AR (1)	AR013358A1 (pl)
AT (2)	ATE309236T1 (pl)
AU (1)	AU731497B2 (pl)
BG (1)	BG64952B1 (pl)
BR (1)	BRPI9810555A8 (pl)
CA (1)	CA2296012C (pl)
CO (1)	CO4940501A1 (pl)
CZ (1)	CZ297904B6 (pl)
DE (2)	DE69840693D1 (pl)
DK (1)	DK1019389T3 (pl)
EE (1)	EE04566B1 (pl)
EG (1)	EG24464A (pl)
ES (2)	ES2251088T3 (pl)
GE (1)	GEP20032897B (pl)
HU (1)	HU227444B1 (pl)
ID (1)	ID23771A (pl)
IL (1)	IL133613A (pl)
LV (1)	LV12569B (pl)
MY (1)	MY124151A (pl)
NO (1)	NO322494B1 (pl)
NZ (1)	NZ501198A (pl)
PE (1)	PE104599A1 (pl)
PL (1)	PL197404B1 (pl)
RO (1)	RO120340B1 (pl)
TR (1)	TR200000065T2 (pl)
TW (1)	TW562802B (pl)
WO (1)	WO1999002514A2 (pl)

Families Citing this family (175)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5969145A (en) *	1996-08-30	1999-10-19	Novartis Ag	Process for the production of epothilones and intermediate products within the process
ATE267197T1 (de) *	1996-11-18	2004-06-15	Biotechnolog Forschung Gmbh	Epothilon d, dessen herstellung und dessen verwendung als cytostatisches mittel bzw. als pflanzenschutzmittel
EP1386922B1 (en)	1996-12-03	2012-04-11	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereof, analogues and uses thereof
US6204388B1 (en) *	1996-12-03	2001-03-20	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
US6867305B2 (en)	1996-12-03	2005-03-15	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
US20050043376A1 (en) *	1996-12-03	2005-02-24	Danishefsky Samuel J.	Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6441186B1 (en)	1996-12-13	2002-08-27	The Scripps Research Institute	Epothilone analogs
US6380394B1 (en)	1996-12-13	2002-04-30	The Scripps Research Institute	Epothilone analogs
US6660758B1 (en)	1996-12-13	2003-12-09	The Scripps Research Institute	Epothilone analogs
US6605599B1 (en)	1997-07-08	2003-08-12	Bristol-Myers Squibb Company	Epothilone derivatives
ES2290993T3 (es)	1997-08-09	2008-02-16	Bayer Schering Pharma Aktiengesellschaft	Nuevos derivados de epotilona, proceso para su produccion y su utilizacion farmaceutica.
US6365749B1 (en) *	1997-12-04	2002-04-02	Bristol-Myers Squibb Company	Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
US6683100B2 (en)	1999-01-19	2004-01-27	Novartis Ag	Organic compounds
US6194181B1 (en)	1998-02-19	2001-02-27	Novartis Ag	Fermentative preparation process for and crystal forms of cytostatics
US6302838B1 (en)	1998-02-25	2001-10-16	Novartis Ag	Cancer treatment with epothilones
FR2775187B1 (fr)	1998-02-25	2003-02-21	Novartis Ag	Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6399638B1 (en) *	1998-04-21	2002-06-04	Bristol-Myers Squibb Company	12,13-modified epothilone derivatives
US6498257B1 (en) *	1998-04-21	2002-12-24	Bristol-Myers Squibb Company	2,3-olefinic epothilone derivatives
DE19826988A1 (de) *	1998-06-18	1999-12-23	Biotechnolog Forschung Gmbh	Epothilon-Nebenkomponenten
CN100381566C (zh)	1998-11-20	2008-04-16	科森生物科学公司	产生环氧噻酮及其衍生物的重组方法和材料
US6410301B1 (en)	1998-11-20	2002-06-25	Kosan Biosciences, Inc.	Myxococcus host cells for the production of epothilones
BR9916833A (pt) *	1998-12-22	2001-09-25	Novartis Ag	Derivados de epotilona e seu uso como agentes antitumor
US6780620B1 (en) *	1998-12-23	2004-08-24	Bristol-Myers Squibb Company	Microbial transformation method for the preparation of an epothilone
EE200100422A (et)	1999-02-11	2002-12-16	Schering Aktiengesellschaft	Epotilooni derivaadid, nende valmistamismeetod jafarmatseutiline kasutamine
US7125875B2 (en)	1999-04-15	2006-10-24	Bristol-Myers Squibb Company	Cyclic protein tyrosine kinase inhibitors
CA2366932C (en)	1999-04-15	2009-08-25	Bristol-Myers Squibb Company	Cyclic protein tyrosine kinase inhibitors
US7125893B1 (en)	1999-04-30	2006-10-24	Schering Ag	6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations
JP4776843B2 (ja)	1999-10-01	2011-09-21	イムノゲンインコーポレーティッド	免疫複合体及び化学療法剤を用いる癌治療用組成物及び方法
US6518421B1 (en)	2000-03-20	2003-02-11	Bristol-Myers Squibb Company	Process for the preparation of epothilone analogs
DE10020899A1 (de) *	2000-04-20	2001-10-25	Schering Ag	9-Oxa-Epothilon-Derivate, Verfahren zu deren Herstellung sowie ihre Verwendung in pharmazeutischen Präparaten
US6489314B1 (en)	2001-04-03	2002-12-03	Kosan Biosciences, Inc.	Epothilone derivatives and methods for making and using the same
US20020045609A1 (en) *	2000-05-26	2002-04-18	Gary Ashley	Epothilone derivatives and methods for making and using the same
UA75365C2 (en) *	2000-08-16	2006-04-17	Bristol Myers Squibb Co	Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
US6989450B2 (en)	2000-10-13	2006-01-24	The University Of Mississippi	Synthesis of epothilones and related analogs
NZ526871A (en) *	2001-01-25	2006-01-27	Bristol Myers Squibb Co	Pharmaceutical dosage forms of epothilones for oral administration
DE60225666T2 (de)	2001-01-25	2009-04-16	Bristol-Myers Squibb Co.	Verfahren zur herstellung von pharmazeutischen zusammensetzungen enthaltend epothilon-analoga zur krebsbehandlung
SK8552003A3 (en) *	2001-01-25	2004-06-08	Bristol Myers Squibb Co	Parenteral formulation containing epothilone analogs
CA2434526C (en) *	2001-01-25	2011-11-01	Bristol Myers Squibb Company	Methods of administering epothilone analogs for the treatment of cancer
US6893859B2 (en)	2001-02-13	2005-05-17	Kosan Biosciences, Inc.	Epothilone derivatives and methods for making and using the same
EE200300397A (et)	2001-02-20	2003-12-15	Bristol-Myers Squibb Company	Epotilooni derivaadid refraktaarsete kasvajate raviks
IL156988A0 (en) *	2001-02-20	2004-02-08	Bristol Myers Squibb Co	Pharmaceutical compositions containing epothilone derivatives
ATE335746T1 (de)	2001-02-27	2006-09-15	Biotechnolog Forschung Gmbh	Verfahren zur herstellung von epothilonen
ATE554756T1 (de) *	2001-03-14	2012-05-15	Bristol Myers Squibb Co	Kombination aus epothilon-analog und chemotherapeutika zur behandlung von proliferativen erkrankungen
US6800653B2 (en)	2001-06-01	2004-10-05	Bristol-Myers Squibb Compnay	Epothilone derivatives
TWI315982B (en)	2001-07-19	2009-10-21	Novartis Ag	Combinations comprising epothilones and pharmaceutical uses thereof
AU2003235761A1 (en)	2002-01-14	2003-07-24	Novartis Ag	Combinations comprising epothilones and anti-metabolites
EP1340498A1 (en) *	2002-03-01	2003-09-03	Schering Aktiengesellschaft	Use of epothilones in the treatment of brain diseases associated with proliferative processes
US7211593B2 (en) *	2002-03-12	2007-05-01	Bristol-Myers Squibb Co.	C12-cyano epothilone derivatives
AU2003218110A1 (en)	2002-03-12	2003-09-29	Bristol-Myers Squibb Company	C3-cyano epothilone derivatives
TW200403994A (en)	2002-04-04	2004-03-16	Bristol Myers Squibb Co	Oral administration of EPOTHILONES
TW200400191A (en) *	2002-05-15	2004-01-01	Bristol Myers Squibb Co	Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
US7405234B2 (en)	2002-05-17	2008-07-29	Bristol-Myers Squibb Company	Bicyclic modulators of androgen receptor function
WO2003105828A1 (en)	2002-06-14	2003-12-24	Bristol-Myers Squibb Company	Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
DE10232094A1 (de) *	2002-07-15	2004-02-05	GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF)	5-Thiaepothilone und 15-disubstituierte Epothilone
US6921769B2 (en)	2002-08-23	2005-07-26	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
US7649006B2 (en)	2002-08-23	2010-01-19	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
ATE350383T1 (de)	2002-08-23	2007-01-15	Sloan Kettering Inst Cancer	Synthese von epothilonen, zwischenprodukte dafür, analoga und deren verwendungen
HRP20050278A2 (en)	2002-09-23	2005-10-31	Bristol-Myers Squibb Company	Methods for the preparation, isolation and purification of epothilone b, and x-ray crystal structures of epothilone b
AU2003264822A1 (en) *	2002-10-11	2004-05-04	Dana-Farber Cancer Institute Inc	Epothilone derivatives for the treatment of multiple myeloma
EP1567487A4 (en)	2002-11-15	2005-11-16	Bristol Myers Squibb Co	OPEN-CHAINED, PROLYL-FROSTED MODULATORS OF ANDROGEN RECEPTOR FUNCTION
US7645782B2 (en) *	2002-11-28	2010-01-12	Wolfgang Richter	Thia-epothilone derivatives for the treatment of cancer
CA2510610A1 (en) *	2002-12-09	2004-06-24	Novartis Ag	Microtubule stabilisers for treating stenosis in stents
GB0230024D0 (en) *	2002-12-23	2003-01-29	Novartis Ag	Organic compounds
CN100359014C (zh) *	2003-01-28	2008-01-02	北京华昊中天生物技术有限公司	一类新型埃坡霉素化合物及其制备方法和用途
EP1594854B1 (en)	2003-02-06	2010-09-01	Bristol-Myers Squibb Company	Thiazolyl-based compounds useful as kinase inhibitors
AU2008200555C1 (en) *	2003-03-14	2011-12-15	Novartis Ag	Treatment of proliferative diseases with epothilone derivatives and radiation
GB0305928D0 (en) *	2003-03-14	2003-04-23	Novartis Ag	Organic compounds
US7371759B2 (en)	2003-09-25	2008-05-13	Bristol-Myers Squibb Company	HMG-CoA reductase inhibitors and method
DE10344882A1 (de) *	2003-09-26	2005-04-21	Morphochem Ag Komb Chemie	Neue Makrocyclen zur Behandlung von Krebserkrankungen
US20050171167A1 (en) *	2003-11-04	2005-08-04	Haby Thomas A.	Process and formulation containing epothilones and analogs thereof
WO2005054429A2 (en) *	2003-11-19	2005-06-16	The University Of Mississippi	Synthesis of the c1-c6 keto-acid synthon of the epothilones
US7420059B2 (en)	2003-11-20	2008-09-02	Bristol-Myers Squibb Company	HMG-CoA reductase inhibitors and method
EP1559447A1 (en)	2004-01-30	2005-08-03	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism
US7820702B2 (en)	2004-02-04	2010-10-26	Bristol-Myers Squibb Company	Sulfonylpyrrolidine modulators of androgen receptor function and method
US7378426B2 (en)	2004-03-01	2008-05-27	Bristol-Myers Squibb Company	Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US7625923B2 (en)	2004-03-04	2009-12-01	Bristol-Myers Squibb Company	Bicyclic modulators of androgen receptor function
US7696241B2 (en)	2004-03-04	2010-04-13	Bristol-Myers Squibb Company	Bicyclic compounds as modulators of androgen receptor function and method
US7459562B2 (en)	2004-04-23	2008-12-02	Bristol-Myers Squibb Company	Monocyclic heterocycles as kinase inhibitors
TW200538453A (en)	2004-04-26	2005-12-01	Bristol Myers Squibb Co	Bicyclic heterocycles as kinase inhibitors
US20090004277A1 (en) *	2004-05-18	2009-01-01	Franchini Miriam K	Nanoparticle dispersion containing lactam compound
US7439246B2 (en)	2004-06-28	2008-10-21	Bristol-Myers Squibb Company	Fused heterocyclic kinase inhibitors
US20050288290A1 (en)	2004-06-28	2005-12-29	Borzilleri Robert M	Fused heterocyclic kinase inhibitors
US7432373B2 (en)	2004-06-28	2008-10-07	Bristol-Meyers Squibb Company	Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
WO2006017761A2 (en) *	2004-08-05	2006-02-16	Emory University	Epothilone analogues as therapeutic agents
EP1640004A1 (en) *	2004-09-24	2006-03-29	Schering Aktiengesellschaft	Use of epothilones in the treatment of bone metastases and bone tumors or cancers
US8232244B2 (en)	2007-02-08	2012-07-31	The Board Of Trustees Of The University Of Illinois	Compositions and methods to prevent cancer with cupredoxins
SI1817013T1 (sl)	2004-11-18	2008-12-31	Bristol Myers Squibb Co	Peleta z gastrorezistentno oblogo, ki vsebuje iksabepilon
WO2006055742A1 (en) *	2004-11-18	2006-05-26	Bristol-Myers Squibb Company	Enteric coated bead comprising epothilone or epothilone analog, and preparation and administration thereof
US20060121511A1 (en)	2004-11-30	2006-06-08	Hyerim Lee	Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
EP1674098A1 (en)	2004-12-23	2006-06-28	Schering Aktiengesellschaft	Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water
EP2634252B1 (en)	2005-02-11	2018-12-19	University of Southern California	Method of expressing proteins with disulfide bridges
WO2006122408A1 (en)	2005-05-18	2006-11-23	Aegera Therapeutics Inc.	Bir domain binding compounds
US7348325B2 (en)	2005-11-30	2008-03-25	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
CA2647565A1 (en)	2006-03-31	2007-10-18	Bristol-Myers Squibb Company	Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
US8008256B2 (en) *	2006-05-01	2011-08-30	University Of Southern California	Combination therapy for treatment of cancer
BRPI0711591A2 (pt)	2006-05-16	2011-11-16	Aegera Therapeutics, Inc.	composto de ligação de domìnio bir da iap
AU2007329375A1 (en)	2006-12-04	2008-06-12	The Board Of Trustees Of The University Of Illinois	Compositions and methods to treat cancer with cupredoxins and CpG rich DNA
CN101754969A (zh) *	2007-05-25	2010-06-23	百时美施贵宝公司	制备埃坡霉素化合物和类似物的方法
US20090076099A1 (en) *	2007-09-14	2009-03-19	Protia, Llc	Deuterium-enriched ixabepilone
EP2065054A1 (en)	2007-11-29	2009-06-03	Bayer Schering Pharma Aktiengesellschaft	Combinations comprising a prostaglandin and uses thereof
EP2070521A1 (en)	2007-12-10	2009-06-17	Bayer Schering Pharma Aktiengesellschaft	Surface-modified nanoparticles
DE102007059752A1 (de)	2007-12-10	2009-06-18	Bayer Schering Pharma Aktiengesellschaft	Funktionalisierte, feste Polymernanopartikel enthaltend Epothilone
US8449886B2 (en) *	2008-01-08	2013-05-28	Bristol-Myers Squibb Company	Combination of anti-CTLA4 antibody with tubulin modulating agents for the treatment of proliferative diseases
CN102076339A (zh) *	2008-04-24	2011-05-25	百时美施贵宝公司	埃坡霉素D在治疗包括阿尔茨海默病的τ相关疾病中的用途
US8802394B2 (en)	2008-11-13	2014-08-12	Radu O. Minea	Method of expressing proteins with disulfide bridges with enhanced yields and activity
EP2210584A1 (en)	2009-01-27	2010-07-28	Bayer Schering Pharma Aktiengesellschaft	Stable polymeric composition comprising an epothilone and an amphiphilic block copolymer
JP4500951B1 (ja) *	2009-08-07	2010-07-14	学校法人神戸学院	Ｄｎａ合成酵素阻害剤
WO2011049625A1 (en)	2009-10-20	2011-04-28	Mansour Samadpour	Method for aflatoxin screening of products
LT2496567T (lt)	2009-11-05	2017-11-27	Rhizen Pharmaceuticals S.A.	Nauji benzopirano kinazės moduliatoriai
NZ602368A (en)	2010-02-12	2014-10-31	Pharmascience Inc	Iap bir domain binding compounds
JP5960688B2 (ja)	2010-05-17	2016-08-02	インコゼンセラピューティクスプライベートリミテッド	プロテインキナーゼ調節物質としての新規３，５−二置換−３ｈ−［１，２，３］トリアゾロ［４，５−ｂ］ピリジン化合物
CA2927832C (en)	2010-05-18	2021-03-23	Cerulean Pharma Inc.	Cyclodextrin-containing polymer-therapeutic agent conjugates and their use
WO2011153221A1 (en)	2010-06-01	2011-12-08	Plus Chemicals Sa	Solid state forms of ixabepilone
CN101906099A (zh) *	2010-07-16	2010-12-08	泰州市今朝伟业精细化工有限公司	一种埃博霉素d-内酰胺衍生物化学合成方法
CA2824521C (en)	2011-01-20	2016-06-28	Board Of Regents, The University Of Texas System	Mri markers, delivery and extraction systems, and related methods
US20140087309A1 (en) *	2011-04-01	2014-03-27	The Research Foundation Of State University Of New York	Olefin-triggered acid amplifiers
US20140193752A1 (en) *	2011-04-01	2014-07-10	The Research Foundation Of State University Of New York	Stabilized acid amplifiers
PT2705029T (pt)	2011-05-04	2019-02-01	Rhizen Pharmaceuticals S A	Novos compostos como moduladores de proteína quinases
JP2014516075A (ja)	2011-06-06	2014-07-07	シェブロンフィリップスケミカルカンパニーエルピー	癌治療のためのメタロセン化合物の使用
EP2717916B1 (en)	2011-06-10	2017-03-08	Mersana Therapeutics, Inc.	Protein-polymer-drug conjugates
CN102863474A (zh)	2011-07-09	2013-01-09	陈小平	一类治疗细胞增殖性疾病的铂化合物、其制备方法和应用
WO2013008091A1 (en) *	2011-07-13	2013-01-17	Xellia Pharmaceuticals Aps	Manufacturing of epothilone derivatives and the use thereof
ES2458220T3 (es)	2011-09-12	2014-04-30	Agfa-Gevaert	Métodos para el marcado por láser color de precursores de documento de seguridad
CN102993239A (zh)	2011-09-19	2013-03-27	陈小平	离去基团含氨基或烷胺基的丁二酸衍生物的铂类化合物
CA2858806A1 (en)	2011-12-23	2013-06-27	Innate Pharma	Enzymatic conjugation of polypeptides
CN104321322A (zh)	2012-03-30	2015-01-28	理森制药股份公司	作为c-met蛋白激酶调节剂的新型3,5-二取代-3h-咪唑并[4,5-b]吡啶和3,5-二取代-3h-[1,2,3]三唑并[4,5-b]吡啶化合物
EP2872894B1 (en)	2012-07-13	2019-04-17	Innate Pharma	Screening of conjugated antibodies
EP2916872B1 (en)	2012-11-09	2019-02-27	Innate Pharma	Recognition tags for tgase-mediated conjugation
EP2924044B1 (en)	2012-11-17	2018-10-31	Beijing Shuobai Pharmaceutical Co., LTD	Platinum compound of malonic acid derivative having leaving group containing amino or alkylamino
US9353150B2 (en)	2012-12-04	2016-05-31	Massachusetts Institute Of Technology	Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
WO2014093394A1 (en)	2012-12-10	2014-06-19	Mersana Therapeutics, Inc.	Protein-polymer-drug conjugates
US9872918B2 (en)	2012-12-12	2018-01-23	Mersana Therapeutics, Inc.	Hydroxyl-polymer-drug-protein conjugates
US9309259B2 (en)	2013-03-08	2016-04-12	Scinopharm Taiwan, Ltd.	Process for ixabepilone, and intermediates thereof
WO2014144715A1 (en)	2013-03-15	2014-09-18	Memorial Sloan-Kettering Cancer Center	Hsp90-targeted cardiac imaging and therapy
US10611824B2 (en)	2013-03-15	2020-04-07	Innate Pharma	Solid phase TGase-mediated conjugation of antibodies
JP2016520665A (ja)	2013-06-11	2016-07-14	バイエル・ファルマ・アクティエンゲゼルシャフト	Ｍｐｓ−１キナーゼ阻害剤および有糸分裂阻害剤を含む、癌の治療のための組合わせ
WO2014202773A1 (en)	2013-06-20	2014-12-24	Innate Pharma	Enzymatic conjugation of polypeptides
KR20160042871A (ko)	2013-06-21	2016-04-20	이나뜨 파르마, 에스.아.	폴리펩티드의 효소적 콘쥬게이션
WO2015054659A1 (en)	2013-10-11	2015-04-16	Mersana Therapeutics, Inc.	Protein-polymer-drug conjugates
CA2927022C (en)	2013-10-11	2018-08-21	Asana Biosciences, Llc	Protein-polymer-drug conjugates
US10341459B2 (en)	2015-09-18	2019-07-02	International Business Machines Corporation	Personalized content and services based on profile information
US10918627B2 (en)	2016-05-11	2021-02-16	Massachusetts Institute Of Technology	Convergent and enantioselective total synthesis of Communesin analogs
US11617799B2 (en)	2016-06-27	2023-04-04	Tagworks Pharmaceuticals B.V.	Cleavable tetrazine used in bio-orthogonal drug activation
US11135307B2 (en)	2016-11-23	2021-10-05	Mersana Therapeutics, Inc.	Peptide-containing linkers for antibody-drug conjugates
US11932650B2 (en)	2017-05-11	2024-03-19	Massachusetts Institute Of Technology	Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10772971B2 (en)	2017-06-22	2020-09-15	Mersana Therpeutics, Inc.	Methods of producing drug-carrying polymer scaffolds and protein-polymer-drug conjugates
US10640508B2 (en)	2017-10-13	2020-05-05	Massachusetts Institute Of Technology	Diazene directed modular synthesis of compounds with quaternary carbon centers
WO2019092148A1 (en)	2017-11-10	2019-05-16	Innate Pharma	Antibodies with functionalized glutamine residues
CA3099419A1 (en)	2018-05-04	2019-11-07	Tagworks Pharmaceuticals B.V.	Tetrazines for high click conjugation yield in vivo and high click release yield
AU2019262521B2 (en)	2018-05-04	2024-04-18	Tagworks Pharmaceuticals B.V.	Compounds comprising a linker for increasing transcyclooctene stability
CA3117050A1 (en)	2018-10-29	2020-05-07	Mersana Therapeutics, Inc.	Cysteine engineered antibody-drug conjugates with peptide-containing linkers
WO2020247054A1 (en)	2019-06-05	2020-12-10	Massachusetts Institute Of Technology	Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
WO2020256546A1 (en)	2019-06-17	2020-12-24	Tagworks Pharmaceuticals B.V.	Compounds for fast and efficient click release
IL289094A (en)	2019-06-17	2022-02-01	Tagworks Pharmaceuticals B V	Tetrazines for increasing the speed and yield of the "click release" reaction
EP4087545A1 (en)	2020-01-10	2022-11-16	R-Pharm US Operating LLC	Compositions of ixabepilone
WO2022182415A1 (en)	2021-02-24	2022-09-01	Massachusetts Institute Of Technology	Himastatin derivatives, and processes of preparation thereof, and uses thereof
EP4399283A2 (en)	2021-09-06	2024-07-17	Veraxa Biotech GmbH	Novel aminoacyl-trna synthetase variants for genetic code expansion in eukaryotes
JP2024543916A (ja)	2021-11-25	2024-11-26	ヴェラクサバイオテックゲーエムベーハー	遺伝暗号拡張を利用した部位特異的結合によって調製された改良された抗体ペイロード複合体（ａｐｃ）
DK4186529T3 (da)	2021-11-25	2025-08-25	Veraxa Biotech Gmbh	Forbedrede antistof-payload-konjugater (apc) fremstillet ved stedspecifik konjugering ved hjælp af genetisk kodeudvidelse
KR20240119102A (ko)	2021-12-08	2024-08-06	유럽피안 몰레큘러 바이올로지 래보러토리	표적화 접합체의 제조를 위한 친수성 테트라진-관능화 페이로드
EP4372000B1 (en)	2022-02-15	2026-06-17	Tagworks Pharmaceuticals B.V.	Masked il12 protein
KR20250049568A (ko)	2022-07-15	2025-04-11	페온 테라퓨틱스 리미티드	Cdcp1에 결합하는 항체 약물 접합체 및 이의 용도
IL320221A (en)	2022-10-12	2025-06-01	Tagworks Pharmaceuticals B V	Strained bicyclo-nonanes
CN120569216A (zh)	2023-01-20	2025-08-29	巴斯夫欧洲公司	稳定型生物聚合物组合物、其制造和用途
JP2026509291A (ja)	2023-03-10	2026-03-17	タグワークスファーマシューティカルスビー．ブイ．	向上されたｔ－リンカーを有するトランス－シクロオクテン
EP4750750A1 (en)	2023-07-27	2026-06-03	Veraxa Biotech GmbH	Hydrophilic trans-cyclooctene (hytco) compounds, constructs and conjugates containing the same
CN122206462A (zh)	2023-09-15	2026-06-12	巴斯夫欧洲公司	稳定型生物聚合物组合物、其制造和用途
WO2025149667A1 (en)	2024-01-12	2025-07-17	Pheon Therapeutics Ltd	Antibody drug conjugates and uses thereof
WO2025174248A1 (en)	2024-02-16	2025-08-21	Tagworks Pharmaceuticals B.V.	Trans-cyclooctenes with "or gate" release
TW202617187A (zh)	2024-08-22	2026-05-01	荷蘭商泰格沃克斯製藥有限公司	反-環辛烯調配物
WO2026064527A1 (en)	2024-09-19	2026-03-26	Tesseract Medicines Us, Llc	Kras-targeting covalent-induced drug conjugates comprising a tubulin inhibitor payload
WO2026064520A1 (en)	2024-09-19	2026-03-26	Tesseract Medicines Us, Llc	Covalent-induced drug conjugates targeting kras and comprising a tubulin inhibitor payload
WO2026078060A1 (en)	2024-10-08	2026-04-16	Basf Se	Tocopherol alkoxylates for biopolymer stabilization
US20260137674A1 (en)	2024-10-23	2026-05-21	Incyte Corporation	Combination therapy using a kras g12d inhibitor, and a nucleoside analog, and/or a microtubule inhibitor
WO2026139575A1 (en)	2024-12-23	2026-07-02	Veraxa Biotech Gmbh	Novel tco-functionalized glycan engineered immunoglobulin molecules, novel tco-functionalized saccharide compounds for preparing the same, and novel antibody payload conjugates

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4272525A (en) *	1978-10-23	1981-06-09	Schering Corporation	Derivatives of polyene macrolide antibiotics containing an amino sugar moiety, process for the preparation thereof, and pharmaceutical compositions containing them
US4820695A (en) *	1982-09-13	1989-04-11	Eli Lilly And Company	C-20-dihydro-deoxy-(cyclic amino)-derivatives of macrolide antibiotics
AU561147B2 (en)	1982-09-13	1987-04-30	Eli Lilly And Company	20-amino macrolide antibiotics
US5411947A (en)	1989-06-28	1995-05-02	Vestar, Inc.	Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
JPH03101679A (ja)	1989-09-14	1991-04-26	Sankyo Co Ltd	リゾキシン誘導体
US5798345A (en) *	1990-09-21	1998-08-25	Bone Care International, Inc.	Method of inhibiting the hyperproliferation of malignant cells
US5789397A (en) *	1991-01-08	1998-08-04	Bone Care International, Inc.	Methods for preparation and use of 1A,24(S)-dihydroxy vitamin D2
CA2067520A1 (en)	1991-05-02	1992-11-03	Tats Matsuoka	Treatment of mastitis
US5217960A (en)	1991-05-03	1993-06-08	Abbott Laboratories	Erythromycin derivatives
JP3101679B2 (ja)	1991-07-02	2000-10-23	株式会社ニチレイ	動物細胞の凍結保存用血清不含培地及び保存方法
DE4138042C2 (de)	1991-11-19	1993-10-14	Biotechnolog Forschung Gmbh	Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
US5795882A (en) *	1992-06-22	1998-08-18	Bone Care International, Inc.	Method of treating prostatic diseases using delayed and/or sustained release vitamin D formulations
TW226373B (pl) *	1992-07-15	1994-07-11	Pfizer
EP0586738A1 (en)	1992-09-11	1994-03-16	Boehringer Ingelheim Vetmedica Gmbh	Enhanced chemotherapeutic compositions against microbial infections in fish containing a benzylamine derivative and an antimicrobial substance
CZ276893A3 (en)	1992-12-21	1994-07-13	Lilly Co Eli	Pharmaceutical preparation for treating gramm-positive disease even of water animals
US5677287A (en)	1993-03-18	1997-10-14	Pfizer Inc.	Antibacterial 16-membered ring macrolides containing olefins at C-20
DE4316836A1 (de)	1993-05-19	1994-11-24	Knoell Hans Forschung Ev	Tetrahydrofuranyl-propionsäure, ein Verfahren zu ihrer Herstellung und Verwendung derselben
AU6980094A (en) *	1993-07-15	1995-02-13	Pfizer Inc.	Amide derivatives of 16-membered ring antibiotic macrolides
EP0639644A1 (de) *	1993-08-16	1995-02-22	Ciba-Geigy Ag	Neue Makrolide und ihre Verwendung
US5763429A (en) *	1993-09-10	1998-06-09	Bone Care International, Inc.	Method of treating prostatic diseases using active vitamin D analogues
WO1996009312A1 (en)	1994-09-22	1996-03-28	Pfizer Inc.	Antibiotic macrolides
AU3953595A (en)	1994-10-07	1996-05-02	Merck & Co., Inc.	Process for assessing tubulin protein polymerization
IL117200A0 (en)	1995-02-21	1996-06-18	Schering Ag	Diethylenetriamine-pentaacetic acid monoamide derivatives pharmaceutical compostions containing the same and processes for the preparation thereof
US6124453A (en) *	1995-07-04	2000-09-26	Novartis Ag	Macrolides
US5515936A (en) *	1995-07-10	1996-05-14	Vehicules Ts Bellechasse Ltee	Track tensioning system for endless track propelled vehicle
DE19542986A1 (de)	1995-11-17	1997-05-22	Biotechnolog Forschung Gmbh	Epothilon-Derivate und deren Verwendung
DE59609305D1 (de)	1995-11-17	2002-07-11	Biotechnolog Forschung Gmbh	Epothilon-Derivate und deren Herstellung
DE19639456A1 (de)	1996-09-25	1998-03-26	Biotechnolog Forschung Gmbh	Epothilon-Derivate, Herstellung und Mittel
WO1997019088A1 (en)	1995-11-21	1997-05-29	Hoechst Celanese Corporation	Novel nonlinear optical molecules and polymers incorporating them
EP0778283A3 (en) *	1995-12-05	1998-01-28	Pfizer Inc.	Antibiotic macrolides
AU716610B2 (en)	1996-08-30	2000-03-02	Novartis Ag	Method for producing epothilones, and intermediate products obtained during the production process
DE19645362A1 (de)	1996-10-28	1998-04-30	Ciba Geigy Ag	Verfahren zur Herstellung von Epothilon A und B und Derivaten
DE19636343C1 (de)	1996-08-30	1997-10-23	Schering Ag	Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B
DE19645361A1 (de)	1996-08-30	1998-04-30	Ciba Geigy Ag	Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B, Teil II
GB9623944D0 (en)	1996-11-15	1997-01-08	Zeneca Ltd	Bicyclic amine derivatives
ATE267197T1 (de)	1996-11-18	2004-06-15	Biotechnolog Forschung Gmbh	Epothilon d, dessen herstellung und dessen verwendung als cytostatisches mittel bzw. als pflanzenschutzmittel
US6515016B2 (en)	1996-12-02	2003-02-04	Angiotech Pharmaceuticals, Inc.	Composition and methods of paclitaxel for treating psoriasis
US6204388B1 (en)	1996-12-03	2001-03-20	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
EP1386922B1 (en)	1996-12-03	2012-04-11	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereof, analogues and uses thereof
US6867305B2 (en)	1996-12-03	2005-03-15	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
US6380394B1 (en)	1996-12-13	2002-04-30	The Scripps Research Institute	Epothilone analogs
US6441186B1 (en)	1996-12-13	2002-08-27	The Scripps Research Institute	Epothilone analogs
AT404477B (de)	1997-01-15	1998-11-25	Thal Hermann Dipl Ing	Gebündeltes spannglied und verfahren zur herstellung desselben
DE19701758A1 (de)	1997-01-20	1998-07-23	Wessjohann Ludgar A Dr	Epothilone-Synthesebausteine
EP0975638B1 (de)	1997-02-25	2002-08-07	Gesellschaft für biotechnologische Forschung mbH (GBF)	Seitenkettenmodifizierte epothilone
DE19713970B4 (de)	1997-04-04	2006-08-31	R&D-Biopharmaceuticals Gmbh	Epothilone-Synthesebausteine II - Prenylderivate
JP4065573B2 (ja)	1997-04-18	2008-03-26	ベーリンガー・インゲルハイム・インテルナツィオナール・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング	反応媒体として圧縮二酸化炭素中における二官能性または多官能性基質の選択的オレフィンメタセシス
DE19821954A1 (de)	1997-05-15	1998-11-19	Biotechnolog Forschung Gmbh	Verfahren zur Herstellung eines Epothilon-Derivats
DE19720312A1 (de)	1997-05-15	1998-11-19	Hoechst Ag	Zubereitung mit erhöhter in vivo Verträglichkeit
DE19726627A1 (de)	1997-06-17	1998-12-24	Schering Ag	Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon
US6605599B1 (en)	1997-07-08	2003-08-12	Bristol-Myers Squibb Company	Epothilone derivatives
DK1001951T3 (da)	1997-07-16	2002-12-23	Schering Ag	Thiazolderivater, fremgangsmåde til fremstilling deraf og anvendelse af disse
ES2290993T3 (es)	1997-08-09	2008-02-16	Bayer Schering Pharma Aktiengesellschaft	Nuevos derivados de epotilona, proceso para su produccion y su utilizacion farmaceutica.
US6365749B1 (en)	1997-12-04	2002-04-02	Bristol-Myers Squibb Company	Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
KR20080016756A (ko)	1998-02-05	2008-02-21	노파르티스 아게	유기화합물 함유 조성물
US6194181B1 (en)	1998-02-19	2001-02-27	Novartis Ag	Fermentative preparation process for and crystal forms of cytostatics
CA2322157C (en)	1998-02-25	2012-05-29	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
FR2775187B1 (fr)	1998-02-25	2003-02-21	Novartis Ag	Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6136630A (en) *	1998-06-04	2000-10-24	The Regents Of The University Of Michigan	Method of making a micromechanical device from a single crystal semiconductor substrate and monolithic sensor formed thereby
AU5036999A (en)	1998-06-30	2000-01-17	Schering Aktiengesellschaft	Epothilon derivatives, their preparation process, intermediate products and their pharmaceutical use
CN100381566C (zh)	1998-11-20	2008-04-16	科森生物科学公司	产生环氧噻酮及其衍生物的重组方法和材料
BR9916833A (pt) *	1998-12-22	2001-09-25	Novartis Ag	Derivados de epotilona e seu uso como agentes antitumor
EE200100431A (et)	1999-02-18	2002-12-16	Schering Aktiengesellschaft	16-halogenoepotilooni derivaadid, nende valmistamismeetod ja farmatseutiline kasutamine
US6211412B1 (en)	1999-03-29	2001-04-03	The University Of Kansas	Synthesis of epothilones
US7125893B1 (en)	1999-04-30	2006-10-24	Schering Ag	6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations
AR023792A1 (es)	1999-04-30	2002-09-04	Bayer Schering Pharma Ag	Derivados 6-alquenilo- y 6-alquinilo-epotilona, los procedimientos para prepararlos y su empleo en productos farmaceuticos
US6518421B1 (en)	2000-03-20	2003-02-11	Bristol-Myers Squibb Company	Process for the preparation of epothilone analogs
UA75365C2 (en)	2000-08-16	2006-04-17	Bristol Myers Squibb Co	Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
DE60225666T2 (de)	2001-01-25	2009-04-16	Bristol-Myers Squibb Co.	Verfahren zur herstellung von pharmazeutischen zusammensetzungen enthaltend epothilon-analoga zur krebsbehandlung
SK8552003A3 (en) *	2001-01-25	2004-06-08	Bristol Myers Squibb Co	Parenteral formulation containing epothilone analogs
NZ526871A (en)	2001-01-25	2006-01-27	Bristol Myers Squibb Co	Pharmaceutical dosage forms of epothilones for oral administration
IL156988A0 (en)	2001-02-20	2004-02-08	Bristol Myers Squibb Co	Pharmaceutical compositions containing epothilone derivatives
ATE554756T1 (de) *	2001-03-14	2012-05-15	Bristol Myers Squibb Co	Kombination aus epothilon-analog und chemotherapeutika zur behandlung von proliferativen erkrankungen
US7026362B2 (en)	2001-10-09	2006-04-11	Simax Technologies, Inc.	Sol-gel process utilizing reduced mixing temperatures

1998
- 1998-05-26 US US09/084,542 patent/US6605599B1/en not_active Ceased
- 1998-06-16 KR KR1020007000120A patent/KR100569041B1/ko not_active Expired - Lifetime
- 1998-06-16 AT AT98930300T patent/ATE309236T1/de active
- 1998-06-16 AU AU79720/98A patent/AU731497B2/en not_active Ceased
- 1998-06-16 EP EP04021059A patent/EP1493738B1/en not_active Expired - Lifetime
- 1998-06-16 CN CNB988069067A patent/CN100384834C/zh not_active Expired - Fee Related
- 1998-06-16 DE DE69840693T patent/DE69840693D1/de not_active Expired - Lifetime
- 1998-06-16 ID IDW20000002A patent/ID23771A/id unknown
- 1998-06-16 TR TR2000/00065T patent/TR200000065T2/xx unknown
- 1998-06-16 DK DK98930300T patent/DK1019389T3/da active
- 1998-06-16 RO RO99-01332A patent/RO120340B1/ro unknown
- 1998-06-16 PL PL338003A patent/PL197404B1/pl unknown
- 1998-06-16 JP JP50867399A patent/JP4090514B2/ja not_active Expired - Fee Related
- 1998-06-16 EP EP04028581A patent/EP1531153A1/en not_active Withdrawn
- 1998-06-16 WO PCT/US1998/012550 patent/WO1999002514A2/en not_active Ceased
- 1998-06-16 AT AT04021059T patent/ATE426598T1/de not_active IP Right Cessation
- 1998-06-16 EE EEP200000013A patent/EE04566B1/xx not_active IP Right Cessation
- 1998-06-16 CA CA002296012A patent/CA2296012C/en not_active Expired - Lifetime
- 1998-06-16 HU HU0103111A patent/HU227444B1/hu not_active IP Right Cessation
- 1998-06-16 DE DE69832294T patent/DE69832294T2/de not_active Expired - Lifetime
- 1998-06-16 BR BRPI9810555A patent/BRPI9810555A8/pt active Search and Examination
- 1998-06-16 IL IL13361398A patent/IL133613A/xx not_active IP Right Cessation
- 1998-06-16 ES ES98930300T patent/ES2251088T3/es not_active Expired - Lifetime
- 1998-06-16 CZ CZ20000058A patent/CZ297904B6/cs not_active IP Right Cessation
- 1998-06-16 ES ES04021059T patent/ES2322807T3/es not_active Expired - Lifetime
- 1998-06-16 NZ NZ501198A patent/NZ501198A/en not_active IP Right Cessation
- 1998-06-16 GE GEAP19985171A patent/GEP20032897B/en unknown
- 1998-06-16 EP EP98930300A patent/EP1019389B1/en not_active Expired - Lifetime
- 1998-06-16 EP EP04028580A patent/EP1526133A1/en not_active Withdrawn
- 1998-07-02 TW TW087110722A patent/TW562802B/zh not_active IP Right Cessation
- 1998-07-07 EG EG79298A patent/EG24464A/xx active
- 1998-07-07 PE PE1998000604A patent/PE104599A1/es not_active Application Discontinuation
- 1998-07-07 CO CO98038387A patent/CO4940501A1/es unknown
- 1998-07-08 MY MYPI98003121A patent/MY124151A/en unknown
- 1998-07-08 AR ARP980103322A patent/AR013358A1/es active IP Right Grant
2000
- 2000-01-07 NO NO20000076A patent/NO322494B1/no not_active IP Right Cessation
- 2000-01-10 BG BG104068A patent/BG64952B1/bg unknown
- 2000-02-02 LV LVP-00-17A patent/LV12569B/en unknown
2003
- 2003-04-03 US US10/405,886 patent/US7125899B2/en not_active Expired - Lifetime
2006
- 2006-08-30 US US11/512,623 patent/US7241755B2/en not_active Expired - Lifetime
2007
- 2007-06-13 JP JP2007156260A patent/JP4885067B2/ja not_active Expired - Fee Related
- 2007-06-15 US US11/763,636 patent/US8536327B2/en not_active Expired - Fee Related
2009
- 2009-08-11 US US12/539,496 patent/USRE41895E1/en not_active Expired - Lifetime
- 2009-08-11 US US12/539,498 patent/USRE41893E1/en not_active Expired - Lifetime
- 2009-08-11 US US12/539,492 patent/USRE41911E1/en not_active Expired - Lifetime
2010
- 2010-09-15 US US12/882,769 patent/USRE43003E1/en not_active Expired - Fee Related
2013
- 2013-08-14 US US13/966,613 patent/US8921542B2/en not_active Expired - Fee Related
2014
- 2014-11-25 US US14/553,081 patent/US20150080440A1/en not_active Abandoned

Also Published As

Publication number	Publication date
WO1999002514A2 (en)	1999-01-21
AU7972098A (en)	1999-02-08
CZ297904B6 (cs)	2007-04-25
CN100384834C (zh)	2008-04-30
ES2322807T3 (es)	2009-06-29
BRPI9810555A8 (pt)	2017-09-19
HUP0103111A2 (hu)	2002-04-29
JP4885067B2 (ja)	2012-02-29
RO120340B1 (ro)	2005-12-30
DE69840693D1 (de)	2009-05-07
EP1493738B1 (en)	2009-03-25
CA2296012A1 (en)	1999-01-21
PL197404B1 (pl)	2008-03-31
PL338003A1 (en)	2000-09-25
IL133613A0 (en)	2001-04-30
CA2296012C (en)	2008-10-21
EP1019389B1 (en)	2005-11-09
EE200000013A (et)	2000-08-15
NO322494B1 (no)	2006-10-16
USRE41911E1 (en)	2010-11-02
US20060287371A1 (en)	2006-12-21
TR200000065T2 (tr)	2000-11-21
GEP20032897B (en)	2003-02-25
WO1999002514A3 (en)	2001-05-10
MY124151A (en)	2006-06-30
ATE309236T1 (de)	2005-11-15
EP1019389A2 (en)	2000-07-19
EP1526133A1 (en)	2005-04-27
EP1531153A1 (en)	2005-05-18
EP1493738A1 (en)	2005-01-05
HK1026905A1 (en)	2000-12-29
CZ200058A3 (cs)	2001-01-17
AR013358A1 (es)	2000-12-27
AU731497B2 (en)	2001-03-29
EE04566B1 (et)	2005-12-15
NZ501198A (en)	2001-09-28
US20130331564A1 (en)	2013-12-12
USRE41895E1 (en)	2010-10-26
CO4940501A1 (es)	2000-07-24
KR20010021562A (ko)	2001-03-15
ES2251088T3 (es)	2006-04-16
USRE43003E1 (en)	2011-12-06
EP1019389A4 (en)	2001-11-07
NO20000076L (no)	2000-01-07
JP2002512634A (ja)	2002-04-23
JP2007291121A (ja)	2007-11-08
LV12569B (en)	2001-04-20
US20150080440A1 (en)	2015-03-19
LV12569A (en)	2000-11-20
HK1031731A1 (zh)	2001-06-22
NO20000076D0 (no)	2000-01-07
US8536327B2 (en)	2013-09-17
CN1270589A (zh)	2000-10-18
US7125899B2 (en)	2006-10-24
KR100569041B1 (ko)	2006-04-10
PE104599A1 (es)	2000-01-19
HU227444B1 (en)	2011-06-28
HUP0103111A3 (en)	2003-01-28
BG64952B1 (bg)	2006-10-31
DK1019389T3 (da)	2006-01-16
DE69832294D1 (de)	2005-12-15
US20030220295A1 (en)	2003-11-27
USRE41893E1 (en)	2010-10-26
BG104068A (en)	2000-09-29
IL133613A (en)	2005-11-20
US8921542B2 (en)	2014-12-30
US20070255055A1 (en)	2007-11-01
DE69832294T2 (de)	2006-05-24
JP4090514B2 (ja)	2008-05-28
EG24464A (en)	2009-07-16
ATE426598T1 (de)	2009-04-15
US6605599B1 (en)	2003-08-12
US7241755B2 (en)	2007-07-10
BR9810555A (pt)	2000-08-15
TW562802B (en)	2003-11-21

Publication	Publication Date	Title
NO20000076D0 (no)	2000-01-07	Epothilone-derivater
ATE191481T1 (de)	2000-04-15	Indolderivate als 5-ht1-like agonisten
ATE153341T1 (de)	1997-06-15	5-o-desosaminylerythronolid derivate
HUP9901155A2 (hu)	1999-07-28	Kinazolinszármazékok mint VEGF-inhibítorok
NO923256L (no)	1993-02-22	Pyrrolidyltiokarbapenemderivat
ATE150022T1 (de)	1997-03-15	10-(1-hydroxyethyl)-11-oxo-1- azatricyclo(7.2.0.0.3,8>undec-2-en-2-carbonsäur - derivate
ATE282614T1 (de)	2004-12-15	Phenylharnstoff und phenylthioharnstoffderivate
SE8303910D0 (sv)	1983-07-08	15-deoxi-hydroxiprostaglandiner och forfarande for framstellning derav
NO893453L (no)	1990-03-01	Antibakterielle spiro-forbindelser og fremgangsmaate for deres fremstilling.
NO942758L (no)	1994-07-22	Benzopyraner og beslektede LTB4 antagonister
ZA803251B (en)	1981-05-27	Pyroglutamic acid derivatives and analogs
DE3879258D1 (de)	1993-04-22	Praeparat gegen ulcus.
DK0392560T3 (da)	1996-01-29	Diaminoethylenforbindelser
FI912899A0 (fi)	1991-06-14	Foerfarande foer framstaellning av hexahydroazepinderivat.
SE7711836L (sv)	1978-04-23	Nya 8-azapurin-6-oner
NO875357L (no)	1988-06-23	Kjemiske sammensetninger og deres bruk som brennstoffadditiver.
IE900215L (en)	1990-07-21	BENZO (b) PYRANS
ATE91033T1 (de)	1993-07-15	Photochromische zusammensetzung und diese zusammensetzung enthaltende gegenstaende.
DE3851190D1 (de)	1994-09-29	Makrolid-Derivate.
IE44681L (en)	1977-11-30	Benzofuran derivatives
FI811201L (fi)	1981-10-20	4-hydroxi-1,2-benzisotiazol-3(2h)-on-1,1-dioxid deras salter deras framstaellning och anvaendning
IL105681A (en)	1997-07-13	Diazabicycloalkene derivatives and pharmaceutical compositions containing them
PE20010201A1 (es)	2001-02-19	Piridonas sustituidas de arilo policiclico y heteroarilo que son utiles para la inhibicion selectiva de la cascada de coagulacion